Health Technology Assessment and Economy Group, Center for Exact, Natural and Health Sciences, Federal University of Espírito Santo, Alto Universitário S/N, Guararema, Alegre, Espírito Santo, 29500-000, Brazil.
Eur J Clin Pharmacol. 2022 Nov;78(11):1749-1761. doi: 10.1007/s00228-022-03381-4. Epub 2022 Sep 13.
The involvement of the orexin system in the physiopathology of insomnia has been rapidly increasing in understanding. In this sense, daridorexant was the third orexin receptor antagonist approved by the FDA in January 2022. This review aims to summarize the chemistry, pharmacodynamics, pharmacokinetics, efficacy, safety, and tolerability profile of daridorexant for the treatment of insomnia disorder.
We performed a review of daridorexant for the treatment of insomnia disorder. The search was carried out in Medline via PubMed, Embase, and clinical trials, up to March 2022.
Daridorexant 25 and 50 mg had more significant improvement for the wake after sleep onset (WASO), latency to persistent sleep (LPS), and subjective total sleep time (sTST) than placebo. In addition, daridorexant 50 mg was better for Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) than placebo. The most common adverse events were nasopharyngitis and headache.
Daridorexant was efficacious and safe. Studies that evaluate the long-term safety and compare daridorexant with benzodiazepines, benzodiazepine receptor agonists, sedative antidepressants, and other orexin receptor antagonists are required.
人们对食欲素系统在失眠病理生理学中的作用的理解迅速加深。在这种意义上，达力雷汀是 2022 年 1 月 FDA 批准的第三种食欲素受体拮抗剂。本综述旨在总结达力雷汀治疗失眠症的化学、药效学、药代动力学、疗效、安全性和耐受性特征。
我们对达力雷汀治疗失眠症进行了综述。检索了 Medline 通过 PubMed、Embase 和临床试验，截至 2022 年 3 月。
达力雷汀 25 和 50mg 比安慰剂更显著改善睡眠后觉醒时间（WASO）、持续睡眠潜伏期（LPS）和主观总睡眠时间（sTST）。此外，达力雷汀 50mg 在失眠日间症状和影响问卷（IDSIQ）方面优于安慰剂。最常见的不良反应是鼻咽炎和头痛。
达力雷汀是有效和安全的。需要进行评估长期安全性的研究，并将达力雷汀与苯二氮䓬类药物、苯二氮䓬受体激动剂、镇静性抗抑郁药和其他食欲素受体拮抗剂进行比较。
